GlaxoSmithKline back on track for core growth, as 4th-qtr beats expectations

3 February 2016
gsk-location-big

UK pharma major GlaxoSmithKline (LSE: GSK) today post financials that beat analysts’ forecasts and suggest the company, which is suffering from patent expirations, is back on track for core growth. GSK’s shares moved up 2.07% to £14.555 by 12.42 GMT.

For the fourth quarter of 2015, group turnover came in at £6.286 billion ($9.03 billion), a rise of 4% at constant exchange rates (+2% in £), beating consensus forecasts of analysts polled by Thomson Reuters of £6.256 billion. Core operating profit was £1.36billion, down 18% at CER, with core earnings per share of 18.1 pence (-28% CER) versus 17.9 pence consensus expectations.

At CER, full-year 2005 turnover grew 6% to £23.92 billion, with core operating profit down 9% at £5.73 billion and core EPS 15% lower at 75.7 pence. Pharmaceutical sales declined 7% to £14.2 billion, while vaccine revenues grew 19% to £3.7 billion and consumer health sales leapt 44% to £6.0 billion. For 2016, GSK says it continues to expect core EPS percentage growth to reach double-digits on a constant currency basis.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical